NY-PHILIP-MORRIS-INTL
25.9.2020 12:17:14 CEST | Business Wire | Press release
Philip Morris International (PMI) (NYSE: PM) has released the 11th edition of its Scientific Update, a regularly issued publication on its research efforts to develop and scientifically assess a range of smoke-free alternatives to cigarettes.
The latest edition features an overview of the historic decision made by the U.S. Food and Drug Administration (FDA) to authorize the marketing of the IQOS Tobacco Heating System with reduced exposure information. The Scientific Update explains the various MRTP decisions under U.S. law; the steps, processes, and timeline PMI undertook; and the ongoing post-market surveillance and studies that will monitor the impact of the orders on consumer perceptions, behavior, and health.
“The FDA undertook a scientific and regulatory evaluation of IQOS and determined that it is ‘appropriate for the promotion of public health’” said Dr. Gizelle Baker, director of Global Scientific Engagement at PMI. “In this edition of our Scientific Update, we describe how the regulatory process worked for PMI, what scientific evidence the FDA considered, and the decisions the FDA made.”
After more than three years of scientific and regulatory review of the application, the FDA concluded: “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body's exposure to harmful or potentially harmful chemicals.”
This issue of the Scientific Update also examines the ABOUT Toolbox—a robust portfolio of self-report instruments—created by PMI to evaluate and assess the public health impact of tobacco harm reduction strategies on consumer perceptions and behavior. The ABOUT Toolbox team describes the new Health and Functioning instrument, which measures the perceived health status of adult smokers who switch to smoke-free products. They explain how the framework was prepared, developed, and validated, and detail the information it can provide to public health and regulatory communities.
The update also includes information on scientific events at which PMI has presented, as well as a compendium of PMI’s peer-reviewed publications and independent research into smoke-free products.
The Scientific Update can be found at https://www.pmiscience.com/whats-new/scientific-update-11 .
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the United States. PMI ships a version of its smoke-free devices and consumables authorized by the U.S. Food and Drug Administration to Altria Group, Inc. for sale in the United States under license. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. For more information, please visit www.pmi.com
and www.pmiscience.com
.
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20200925005165/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 15:37:00 CEST | Press release
The new SpeechLive Legal AI Assistant reduces the administrative burden on legal professionals through customizable document drafting powered by speech recognition tuned for legal terminology Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent an
Corpay Cross-Border Named the Official FX Partner of Ultimate Sevens5.8.2026 15:31:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Ultimate Sevens, a new global rugby sevens championship backed by BIA Sports Group launching in August 2026. Under the agreement, Corpay becomes Ultimate Sevens exclusive and Official Foreign Exchange (FX) Partner, along with being an Ultimate Sevens Playmaker. As the Championships’ exclusive foreign exchange partner, Corpay Cross-Border will provide Ultimate Sevens with comprehensive FX risk management solutions to help manage foreign exchange exposure from its day-to-day business activities. Corpay Cross-Border’s award-winning platform will also enable Ultimate Sevens to manage global payments through a single point of access. “Corpay Cross-Border is thrilled to be named the exclusive and official FX partner of Ultimate Sevens,” said Brad Loder,
TestMu AI Makes Samsung Galaxy Z Fold8 and Galaxy Z Fold8 Ultra Available on Real Device Cloud Ahead of Retail Launch5.8.2026 14:30:00 CEST | Press release
Developers can test websites and mobile apps on Samsung's newest foldables, running Android 17, before the devices reach customers TestMu AI (formerly LambdaTest), the world's first full-stack Agentic AI Quality Engineering platform, announced that the Samsung Galaxy Z Fold8 and Galaxy Z Fold8 Ultra are now available for testing on its Real Device Cloud. Both devices, unveiled at Samsung's Galaxy Unpacked event, run Android 17 with One UI 9 and are accessible for live testing and automation before retail units reach customers. The launch generation introduces a testing challenge new to the Galaxy Z Fold line. The Galaxy Z Fold8 unfolds into a portrait-oriented 7.6-inch display, while the Galaxy Z Fold8 Ultra, the first Ultra model in the Z series, unfolds into a landscape-oriented 8.0-inch display. Two devices that share a name, a chipset, and an operating system present layouts with opposite orientations, which means an interface validated on one can break on the other. "Samsung has i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
